Back to products list

Brexpiprazole

StatusPipeline
Therapeutic cat.Neurology
Polymorphic formanhydrous form (from I)
CAS No.913611-97-9
Reference Product
Injectable Form
EU DMF readinessCheckbox
CEPCheckbox
CHINESE  DMFCheckbox
JAPANESE DMFCheckbox
KOREAN  DMFCheckbox
CANADIAN  DMFCheckbox
CADIFACheckbox
US DMF readinessCheckbox
OEB No.
Samples

Drug description

Brexpiprazole is an antipsychotic medication that is used to treat the symptoms of schizophrenia. It is also used together with other medications to treat major depressive disorder in adults. Brexpiprazole may also be used for purposes not listed in this medication guide.

Polpharma API

  • Product of high chemical purity
  • No N-nitrosamine impurities
  • High polymorphic purity after micronization

Disclaimer

Products protected by patents (SPC) in Poland are developed solely for the purpose of Regulatory Submissions or R&D purposes intended to support Regulatory Submissions. These products are not offered for sale or made available in countries where such products are subject to patent (SPC) protection and where the offer for sale or any related activity constitutes patent infringement. It is within the buyer’s responsibility and liability to check the patent situation of the product in the import market(s). Based on exemption under art. 5(2) of the Regulation (EC) No 469/2009 concerning the supplementary protection certificate for medicinal products Apixaban, Dapagliflozin (amorphous), Linagliptin, Rivaroxaban and Ticagrelor, which are protected by SPCs in Poland, can be manufactured and offered only for the purpose of export to non-EU countries, provided all requirements of the Regulationare met.

Have a question?
Our specialists will be happy to guide you through our cooperation process.
Contact us